BioGenCell is led by a team of seasoned executives who have many years of executive and technical experience in the biotechnology industry. The founding team has a proven track record in the creation and manufacturing of commercially available cellular products, which were proven safe and beneficial for treating severe heart diseases and peripheral arterial diseases.

Board Of Management

Yael Porat, PhD

CEO, Founder

Dr. Porat is a specialist in the biotechnology industry, having worked as an innovator, scientist, advisor and director for both industry leaders and pioneering startups.
Prior to founding BioGenCell, Dr. Porat served as CTO for TheraVitae, where she established the R&D and manufacturing departments and was responsible for the research, development and production of the company’s GMP-compliant adult stem cell-based products used for preclinical and clinical studies, as well as for routine treatment of patients.
Previously, Dr. Porat worked for the global R&D division of Teva Pharmaceutical Industries Ltd (Nasdaq: TEVA) as Manager of the Biological Methods Development department where she lead multidisciplinary research teams in development of biological methods supporting pharmaceutical products development. Prior to Teva, she worked for XTL Biopharmaceuticals Ltd (Nasdaq: XTLB) as a senior project manager and member of the project leaders forum in charge of the company’s strategic planning. Dr. Porat, an author of many scientific publications and patents, holds MA and PhD degrees in Immunology from the Sackler School of Medicine, Tel-Aviv University, Israel.

Prof. Michael Belkin, MD

Chief Scientific Officer, Co-Founder

Prof. Belkin has been involved in biotechnology ventures since the creation of the field and was involved in the establishment of over 15 medical start-ups in ophthalmology and other fields. He also serves as a consultant to numerous biotechnology projects and companies.
Prof. Belkin is currently a professor of Ophthalmology and the incumbent of the Fox Chair of Ophthalmology in Tel-Aviv University. He is also the director of the Ophthalmic Technologies Laboratory at the university’s Eye Research Institute located at the Sheba Medical Center, Israel, and serves as senior advisor to the Singapore Eye Research Institute.
Prof. Belkin served previously as Director of Research, Development and Non-conventional Warfare Medicine in the Israel Defense Forces’ Medical Corps, was the first full-time director of the Tel Aviv University Eye Research Institute, Chairman of the Tel-Aviv University Department of Ophthalmology and President of the Israel Society of Eye and Vision Research of which he was a founder.
Prof. Belkin, who is the author of over 200 scientific publications and holds 15 patents, received an MA in Science from Cambridge University, England, and a PhD in Medicine from the Hebrew University of Jerusalem, Israel.

Mr. Eyal Peleg, CPA, MBA

Chief Financial Officer, Co-Founder

Mr. Peleg has over 25 years experience in growing and managing professional teams as a CEO. He is currently a consultant to both start-ups and established companies on the issues of strategic planning, business plans, long and short term contracts as well as  financial and tax planning programs and controlling.
Prior to his CEO positions, Mr. Peleg was a senior partner in an accounting firm responsible for IPOs, evaluations, business plans and controlling. He is a director of several commercial and hi-tech companies and is a member of several national and industrial committees, in charge of national financial regulations.
Mr. Peleg is a certified CPA and holds an MBA degree (financing) from the Recanati Business School of Tel Aviv University, Israel.

Michael Barnea, Adv

Legal Advisor

Mr. Barnea is a senior partner at the law firm of Barnea & Co., where he specializes in technology-related sales, licensing and development transactions, and has advised technology and investment companies on a variety of corporate transactions, including mergers and acquisitions, share purchases, private placements and public offerings on the Tel Aviv, London and Nasdaq stock exchanges.

Mr. Barnea is a graduate of the Tel Aviv University Law School, and served as a teaching assistant at the Recanati Business School of Tel Aviv University, Israel.

Marc Dechamps

BioGenCell EU Administrator

Marc Dechamps is a biologist with extensive experience of more than 30 years in the Pharmaceutical industry, with expertise in market development for new products including infectious diseases, immunological disorders, cancer, CNS diseases and vaccines. He started his career with sales and marketing management positions at corporate pharma companies including Glaxo, Glaxo Wellcome and GSK. His last position was Executive Director of the Commercial department “Specialty care & Vaccines” at GSK . In 2009 he became Head of the European Mid-Size Countries Region at ViiV Healthcare (ViiVHC), a spin out company created by GSK and Pfizer where he created and managed 4 ViiVHC Companies and built a European Commercial – Market Access Operations team dedicated to the launch of the new assets of ViiVHC. Since 2016 Mr. Dechamps has supported biotechnological start-up companies in the field of gene and cell therapies with strategic advising and management leadership. Before joining BioGenCell Marc served as Managing Director of Delphi Genetics, a Belgian Biotech company specialised in the production of plasmid DNA. Marc is also currently acting as Chairman of the Management Committee of eTheRNA, a “round A” Belgian biotech company, involved in Immuno-oncology, developing a specific mRNA platform for boosting the immune system.

Expert Support

Prof. Frank J Veith

Dr. Veith graduated from Cornell University Medical School with Honors before completing an internship at Columbia-Presbyterian Hospital in New York and his surgical residency training at Peter Bent Brigham Hospital and Harvard Medical School.  Dr. Veith achieved success with his pioneering work in experimental and clinical lung transplantation.  In the 1970s and 1980s, Dr. Veith’s attention turned toward Vascular Surgery with an emphasis on lower extremity revascularization procedures. He and his colleagues were the first to advocate an aggressive approach to saving limbs threatened by arteriosclerosis and gangrene when most patients with this problem were being treated by a major amputation.  In the late 1980s and early 1990s Dr. Veith became increasingly involved with endovascular treatments.  He and his group were the first to perform an endovascular graft repair of an abdominal aortic aneurysm or EVAR in the United States.  They also were the first in the world to perform an EVAR for a ruptured abdominal aneurysm. Dr.Veith has held positions in every national vascular society and many international ones.  In 1995 he was elected President of the Society for Vascular Surgery, the most prestigious society in the field.  He has been a leading advocate for the recognition of Vascular Surgery as a separate and distinct specialty and is the past Chairman of the American Board of Vascular Surgery.  Dr. Veith held positions as Chief of Vascular Surgery and Interim Chairman of Surgery at Montefiore Medical Center and Albert Einstein College of Medicine for many years.  He was also The William J. Von Liebig Chair in Vascular Surgery and the Vice Chairman of the Department of Surgery.  Throughout his career he has received numerous awards and honors as a leader, outstanding teacher and innovator in Vascular Surgery.  He is now Professor of Surgery and The William J. von Liebig Chair in Vascular Surgery at the Cleveland Clinic and Professor of Surgery at New York University Medical Center.  As he has done for many years, Dr. Veith also Chairs the largest Vascular Surgery meeting, the VEITHsymposium, held annually in New York City. In June of 2010, Dr. Veith received the SVS Distinguished Lifetime Achievement Award.  In 2013 an endowed chair, the Frank J. Veith Chair in Vascular and Endovascular Surgery, was established at New York University Medical School to honor Dr. Veith. Also in 2013 Dr. Veith received the Lifetime Achievement Award of the Houston Aortic Symposium.

Prof. Aaron Ciechanover

Nobel Prize laureate Prof. Aaron Ciechanover is a Distinguished Research Professor in the Faculty of Medicine at the Technion – Israel Institute of Technology in Haifa, Israel. His groundbreaking discoveries on the ubiquitin system and its major roles in homeostasis and in pathogenetic mechanisms of many diseases have paved the way to new platforms for drug development.
He received his M.D. (1973) from the Hebrew University in Jerusalem and continued his studies to obtain a doctorate in biological sciences in the Faculty of Medicine in the Technion (D.Sc.; 1982). There, as a graduate student with Dr. Avram Hershko and in collaboration with Dr. Irwin A. Rose from the Fox Chase Cancer Center in Philadelphia, USA, they discovered that covalent attachment of ubiquitin to a targetprotein signals it for degradation. They deciphered the mechanism of conjugation, described the general proteolytic functions of the system, and proposed a model according to which this modification serves as a recognition signal for a specific downstream protease. As a post- doctoral fellow with Dr. Harvey Lodish at the M.I.T., he continued his studies on the ubiquitin system and made additional important discoveries. Along the years it has become clear that ubiquitin-mediated proteolysis plays major roles in numerous cellular processes, and aberrations in the system underlie the pathogenetic mechanisms of many diseases, among them certain malignancies and neurodegenerative disorders. Among the numerous prizes Ciechanover received are the 2000 Albert Lasker Award, the 2003 Israel Prize, and the 2004 Nobel Prize (Chemistry; shared with Drs. Hershko and Rose). Among many academies, Prof Ciechanover is a member of the Israeli National Academy of Sciences and Humanities, The European Molecular Biology Organization (EMBO), the American Academy of Arts and Sciences (Foreign Fellow), the American Philosophical Society, the National Academies of Sciences (NAS) and Medicine (NAM) of the USA (Foreign Associate), the Pontifical Academy of Sciences at the Vatican, the Chinese Academy of Sciences (CAS; Foreign Member), the Russian Academy of Sciences (Foreign Member), and the German Academy of Sciences (Leopoldina).

Prof. Martin Grajower

Dr. Martin Grajower, MD, is an endocrinology, diabetes & metabolism specialist in Bronx, NY and has been practicing for 40 years. He graduated from Albert Einstein College of Medicine  in 1973, is board-certified in both specialties and holds the title of Clinical Associate Professor of Medicine, Division of Endocrinology, at Einstein. Dr. Martin Grajower is the vice president of the Lower New York Chapter of the American Association of Clinical Endocrinologist.  He serves on the editorial board of Endocrine Practice and Journal of Hospital Administration, is  co-editor of leading scientific publications and is an endocrine consultant to Prescriber’s Newsletter. Dr. Grajower also serves on many national committees, is a fellow of the American College of Physicians and the American college of Endocrinology, is an Affiliate Physician at Columbia University College of Physicians and Surgeons and maintains a leading private practice in New York. Before advising BioGenCell he served as an Advisory Board member to Bristol-Myers Squibb.

Dr. Michael Frogel

Dr. Frogel is an Associate Professor of Pediatrics at the Albert Einstein College of Medicine, Principal Investigator for the New York City Pediatric Disaster Coalition (PDC) and Medical Director of the Pediatric Disaster Mental Health Initiative at Maimonides Medical Center. He has previously served as Chairman of Pediatrics at Nassau University Medical Center and Chief of General Pediatrics, Urgent Care and Emergency Medicine at Cohen Children’s Medical Center of the NSLIJ Health System.  Dr. Frogel’s main areas of interest are pediatric emergency preparedness, child advocacy, sports medicine and weight management, preventive pediatrics and stem cell research. He has received millions of dollars in grants and created special programs for Pediatric Urgent Care, Women Infants and Children (WIC, Nutrition), Childhood Obesity and Sports Medicine, Autism and Child Abuse during his extensive career in building healthcare systems. Since 2008 he has served as Principal Investigator for the NY City Department of Health, US Health and Human Services, PDC Grant encompassing pediatric emergency preparedness for New York City. Dr. Frogel is recognized as a world expert on Emergency and Disaster Preparedness. He coordinates a yearly course in Israel on Emergency Preparedness. He has frequently visited Israeli cities under attack and has spearheaded campaigns to build shelters at schools and playgrounds. Dr. Frogel is currently applying his expertise in HealthCare System Management to the development of a revolutionary stem cell treatment for vascular diseases that promises to regenerate blood vessels restore tissue function and return patients from disability to full function.

Dr. Mark J Niven

Dr. Niven is the Director of Endocrine and Diabetes Unit, incorporating The Bildirici Center for Diabetes Care and Researchat at Sanz Medical Center–Laniado Hospital, Israel. In addition to making changes in lifestyle, the diabetes patient must enlist the assistance of a wide range of specialists for comprehensive treatment of the disease. A diabetes patient must spend precious time visiting specialists in widely dispersed clinics, searching for information, and evaluating various opinions and recommendations. The patient must see a long list of specialists such as the family physician, endocrinologist/diabetes specialist, ophthalmologist, diabetic podiatrist, and dietician, and in between, undergo laboratory and other tests. All of this demands a significant  expenditure of time and energy. The Gabriel Cabra Bildirici Diabetes Center was established by the Sanz Medical Center–Laniado Hospital to solve this problem and to take into account the needs of the patient and his/her family, with the goal of grouping all the required tests, treatments, and medical experts in one central location. With this overall vision of providing convenient service and improving the patients’ quality of life, the DiabetesCenter provides all the necessary tests and physicians in a wide range of specialties under one roof, thus enabling comprehensive treatment of diabetes. The Bildirici Diabetes Center is the first and only such center in Israel. It operates according to an innovative approach that aims to streamline and shorten the medical process for diabetes patients, thus assisting them to cope with the disease and its side-effects, and to adjust to a new lifestyle. A medical specialist manages each patient’s medical file. This specialist operates in full cooperation with all the other specialists, consulting with them regularly regarding each step and decision regarding the patient. Managing the medical file under one roof saves the patient the aggravation of having to cope with multiple, disparate opinions. The Gabriel Cabra Bildirici Diabetes Center answers treatment needs by offering the services of a multidisciplinary staff in the fields of diabetes, nephrology, ophthalmology, vascular medicine, cardiology, urology, diet and nutrition, psychiatry, social services, and laboratory services. Patient stay in the clinic is several hours. For the patients’ comfort and enjoyment during their stay, the center provides comfortable sitting areas where they may read, write, eat, and drink in an atmosphere that is homey, warm, and considerate.

Dr. Shlomo Bulvik

Dr. Shlomo Bulvik, director of the Hematology Department at at Sanz Medical Center–Laniado Hospital, Israel. Dr. Bulvik is currently involved in two major studies in the field of leukemia. The research which received the approval of the Ethics (Helsinki) Committee, is at an advanced stage involving a great deal of patient participation.  The research at the Hematology Department is focusing on biological and chemical treatment for multiple myeloma and lymphoma. “The world of medicine is marching toward biological treatment,” adds Dr. Bulvik. “The major significance of this is the reduction of side effects, since these drugs are based on human proteins. Furthermore, biological drugs can treat cancer cells in a more targeted fashion.” Patients participating in the study undergo a comprehensive series of tests to ensure that they can undergo the clinical trial and derive the greatest possible benefit from it. “We are at the final, approval stage of a number of additional studies on leukemia and I have no doubt that the benefits to people suffering from cancer will significantly improve their quality of life,” concludes Dr. Bulvik.

Prof. Bruce Bachenheimer

Bruce Bachenheimer is a Clinical Professor of Management and Executive Director of the Entrepreneurship Lab at Pace University. He is also a member of the Board and past Chair of the New York City Chapter of the MIT Enterprise Forum and has served on the organization’s Global Board. He has been widely quoted in a variety of domestic and international publications, interviewed on radio and television and has spoken on entrepreneurship at numerous organizations, including the Youth Assembly at the United Nations and the U.S. Department of State’s International Visitor Leadership Program. Mr. Bachenheimer began his career in investment banking and has worked for global corporations and new ventures. He has conducted business in over two dozen countries and was the founder of Annapolis Maritime Corp. and the Co-Founder of StockCentral Australia. He holds a BBA, Summa Cum Laude, from Pace University and received the McKinsey & Company Leadership Scholarship to pursue an MBA degree, which he earned from the Australian Graduate School of Management.


We'll be happy to hear from you!

Font Resize